NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients

Table 1 Demographic data of 302 patients by nonalcoholic fatty liver disease fibrosis score at baseline n (%) (mean ± SD)

Variable at baseline	Total	Patients with a low probability ofadvanced liver fibrosis	Patients with an intermediate or highprobability of advanced liver fibrosis	P value
	(n = 302)	(NFS < -1.5) (n = 181)	(NFS≥-1.5) (n = 121)
Age (yr)	47.3 ± 12.9	42.9 ± 11.1	53.8 ± 12.8	< 0.0001
Sex (% male)	132 (44)	92 (51)	40 (33)	0.002
Race, number (% White)	288 (95)	170 (94)	119 (97.5)	0.150
History of diabetes	48 (16)	5 (2.8)	43 (35.5)	< 0.0001
History of hypertension	125 (41)	55 (30.4)	70 (58)	< 0.0001
BMI (kg/m2)	33.6 ± 6.2	32.0 ± 5.2	36.0 ± 6.9	< 0.0001
Presence of obesity (BMI > 30 kg/m2)	221 (73)	121 (67)	100 (82.6)	0.002
Systolic blood pressure (mmHg)	136 ± 18	133 ± 17	139 ± 18	0.003
Diastolic blood pressure (mmHg)	83 ± 9	84 ± 8	81 ± 9	0.010
Cholesterol (mg/dL)	214 ± 48	215 ± 46	214 ± 50	0.780
Triglycerides (mg/dL)	221 ± 167	208 ± 123	242 ± 218	0.150
Glucose (mg/dL)	115 ± 41	103 ± 25	132 ± 54	< 0.0001
AST (U/L)	41.4 ± 21.9	40.8 ± 21.8	42.2 ± 28.9	0.620
ALT (U/L)	61.5 ± 43.3	69.7 ± 46	49.4 ± 35.7	< 0.0001
AST/ALT ratio	0.8 ± 0.4	0.7 ± 0.3	1.0 ± 0.6	< 0.0001
GGT (U/L)	131.9 ± 39.8	129.9 ± 32.9	134.2 ± 46.7	0.560
Platelets (× 109/L)	240 ± 62	259 ± 60	212 ± 53	< 0.0001
Albumin (g/dL)	4.3 ± 0.4	4.4 ± 0.3	4.1 ± 0.3	< 0.0001
Alkaline phosphatase (U/L)	196 ± 88	186 ± 68	211 ± 111	0.030
Framingham Risk Score	8.4 ± 6.2	6.9 ± 6.4	10.5 ± 5.2	< 0.0001
Calculated CHD risk (%)	16.2 ± 14.6	14.1 ± 13.8	19.3 ± 15.2	0.003
NFS	-1.7 ± 1.4	-2.6 ± 0.8	-0.4 ± 0.9	< 0.0001

NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Glutamyltransferase; CHD: Coronary heart disease; NFS: NAFLD fibrosis score.